Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel stearoyl-CoA desaturase inhibitors disclosed by Gilead

May 13, 2010

Ferring acquires global rights to Lysteda from Xanodyne

May 12, 2010

Acrux and Vivus sign settlement agreement for Luramist dispute, Vivus license terminated

May 11, 2010

Generex achieves enrollment of over 400 subjects in Generex Oral-lyn study

May 11, 2010

Oramed reports results for phase IIb trial of oral insulin in type 2 diabetes

May 10, 2010

Merck & Co. identifies novel histamine H3 receptor ligands

May 10, 2010

Bayer receives FDA approval for Natazia for prevention of pregnancy

May 7, 2010

FDA review sets new PDUFA action date for Bydureon

May 7, 2010

Novo Nordisk to begin phase III cardiovascular outcomes trial for Victoza in fall 2010

May 7, 2010

BELLUS discontinues NC-503 development for diabetes following proof-of-concept study

May 7, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...